We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
-3.06%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$77.7B
AUM Growth
-$3.9B
(-4.8%)
Cap. Flow
+$505M
Cap. Flow
% of AUM
0.65%
Top 10 Holdings %
Top 10 Hldgs %
24.09%
Holding
3,066
New
55
Increased
1,481
Reduced
1,461
Closed
51
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$83.5M |
| 2 |
S&P Global
SPGI
|
+$73.5M |
| 3 |
Tesla
TSLA
|
+$55.8M |
| 4 |
Microsoft
MSFT
|
+$45.9M |
| 5 |
Amazon
AMZN
|
+$27.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
XLNX
Xilinx Inc
XLNX
|
+$88.8M |
| 2 |
INFO
IHS Markit Ltd. Common Shares
INFO
|
+$74.7M |
| 3 |
CONE
CyrusOne Inc Common Stock
CONE
|
+$31.7M |
| 4 |
Abbott
ABT
|
+$25.5M |
| 5 |
Exelon
EXC
|
+$23.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.74% |
| 2 | Financials | 13.53% |
| 3 | Healthcare | 13.01% |
| 4 | Consumer Discretionary | 11.66% |
| 5 | Industrials | 8.96% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2801
Pliant Therapeutics
PLRX
$65M
| $160K | ﹤0.01% |
22,867
+523
| +2% | +$5.34K |
|
2802
Quantum Corp
QMCO
$474M
| $160K | ﹤0.01% |
3,534
-42
| -1% | -$3.08K |
|
2803
InfuSystem Holdings
INFU
$249M
| $159K | ﹤0.01% |
16,232
+5,021
| +45% | +$64.5K |
|
2804
Rekor Systems
REKR
$91.7M
| $158K | ﹤0.01% |
34,677
+4,803
| +16% | +$22.6K |
|
|
OYST
2805
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
| $158K | ﹤0.01% |
13,531
+2,568
| +23% | +$30.6K |
|
2806
FTC Solar
FTCI
$44.9M
| $157K | ﹤0.01% |
3,183
+1,715
| +117% | +$85.7K |
|
2807
Lineage Cell Therapeutics
LCTX
$278M
| $157K | ﹤0.01% |
101,742
-18,692
| -16% | -$29K |
|
|
ADVM
2808
DELISTED
Adverum Biotechnologies
ADVM
| $156K | ﹤0.01% |
11,921
-967
| -8% | -$14.1K |
|
|
CLPR
2809
Clipper Realty
CLPR
$46.2M
| $156K | ﹤0.01% |
17,247
+213
| +1% | +$1.99K |
|
2810
Stereotaxis
STXS
$141M
| $156K | ﹤0.01% |
41,897
+2,886
| +7% | +$13.6K |
|
2811
Cue Biopharma
CUE
$114M
| $155K | ﹤0.01% |
1,059
-1
| -0.1% | -$212 |
|
2812
Precision BioSciences
DTIL
$207M
| $153K | ﹤0.01% |
1,655
+73
| +5% | +$9.92K |
|
2813
RxSight
RXST
$260M
| $153K | ﹤0.01% |
+12,353
| New | +$148K |
|
2814
The ONE Group
STKS
$53M
| $153K | ﹤0.01% |
14,589
+3,800
| +35% | +$44.7K |
|
|
PSTX
2815
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $153K | ﹤0.01% |
34,064
+3,137
| +10% | +$14.1K |
|
2816
CEL-SCI Corp
CVM
$30.1M
| $152K | ﹤0.01% |
1,293
-16
| -1% | -$2.6K |
|
|
EPZM
2817
DELISTED
Epizyme, Inc
EPZM
| $150K | ﹤0.01% |
130,067
+17,351
| +15% | +$28.3K |
|
|
KG
2818
Kestrel Group
KG
$69M
| $149K | ﹤0.01% |
3,089
-141
| -4% | -$7.42K |
|
|
CASA
2819
DELISTED
Casa Systems, Inc. Common Stock
CASA
| $149K | ﹤0.01% |
32,974
-602
| -2% | -$2.74K |
|
|
EAR
2820
DELISTED
Eargo, Inc. Common Stock
EAR
| $149K | ﹤0.01% |
1,409
+443
| +46% | +$43.8K |
|
2821
Target Hospitality
TH
$1.64B
| $148K | ﹤0.01% |
24,622
-514
| -2% | -$2K |
|
2822
Akebia Therapeutics
AKBA
$252M
| $147K | ﹤0.01% |
205,062
-6,053
| -3% | -$12.9K |
|
|
TRML
2823
DELISTED
Tourmaline Bio
TRML
| $147K | ﹤0.01% |
1,494
+64
| +4% | +$5.99K |
|
2824
Taysha Gene Therapies
TSHA
$1.89B
| $146K | ﹤0.01% |
22,389
+2,619
| +13% | +$19.6K |
|
|
BFX
2825
DELISTED
BowFlex Inc.
BFX
| $145K | ﹤0.01% |
35,145
-2,951
| -8% | -$14.7K |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2022 Portfolio in Review
As of Q1 2022, RhumbLine Advisers held 3,066 positions worth $77.7B, down 4.8% from $81.6B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Trading was light in Q1 2022: portfolio turnover was 3.5%. RhumbLine Advisers opened 55 new positions and exited 51, leaving the 3,066-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 25% of assets, down from 26% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q1 2022 buy was Constellation Energy: 528,261 shares worth $29.7M.
- RhumbLine Advisers added most to Advanced Micro Devices in Q1 2022, an estimated $83.5M increase.
- RhumbLine Advisers's biggest Q1 2022 reduction was Abbott, cutting an estimated $25.5M.
- RhumbLine Advisers fully exited Xilinx Inc in Q1 2022, selling an estimated $88.8M.
- RhumbLine Advisers's ten largest holdings make up 24% of its $77.7B portfolio in Q1 2022.
- RhumbLine Advisers opened 55 new positions and closed 51 in Q1 2022.
- RhumbLine Advisers's portfolio value fell 4.8% quarter-over-quarter to $77.7B.
Based on RhumbLine Advisers's 13F filing for Q1 2022, filed 12 May 2022.